
-
Inter downed by Roma, AC Milan bounce back with victory in Venice
-
Religious hate has no place in France, says Macron after Muslim killed in mosque
-
Last day of Canada election campaign jolted by Vancouver attack
-
Barcelona crush Chelsea to reach women's Champions League final
-
Nine killed as driver plows into Filipino festival in Canada
-
Germany marks liberation of Bergen-Belsen Nazi camp
-
Hojlund strikes at the death to rescue Man Utd in Bournemouth draw
-
Zelensky says Ukraine not kicked out of Russia's Kursk
-
Zverev, Sabalenka battle through in Madrid Open, Rublev defence over
-
Ruthless Pogacar wins Liege-Bastogne-Liege for third time
-
Bumrah claims 4-22 as Mumbai register five straight IPL wins
-
No place for racism, hate in France, says Macron after Muslim killed in mosque
-
Greenland leader says Trump's threats disrespectful
-
Spain's Alex Marquez celebrates maiden MotoGP in home Grand Prix
-
Iran's president visits site of port blast that killed 28
-
French rapper Jul breaks attendance record at national stadium
-
Gaza ministry says hundreds of war missing confirmed dead, toll at 52,243
-
Crowds flock to Pope Francis tomb, as eyes turn to conclave
-
'Godfather' director Coppola bags lifetime achievement award
-
Assefa sets world record, Sawe destroys high class field in London marathon
-
'No excuse': Real Madrid's Rudiger after throwing object at ref
-
Fire blazes day after Iran port blast killed 28, injured 1,000
-
Real Madrid meltdown after third Clasico defeat inevitable end to ugly weekend
-
Nine killed as driver plows into Vancouver festival crowd
-
Crumbs! Should French bakeries open on May 1?
-
All eyes turn to conclave as Pope Francis tomb opens to public
-
Emotional Penge bounces back from betting ban for first DP Tour win
-
25 killed, 1,000 injured in huge Iran port blast
-
Greenland PM visits Denmark as Trump threats loom
-
Philippines, US test air defences as China seizes reef
-
25 killed, fires still burning in huge Iran port blast
-
India and Pakistan troops exchange fire in Kashmir
-
Eighteen killed, fires still burning in huge Iran port blast
-
No handshake at muted India-Pakistan border ceremony
-
Maligned by Trump, White House reporters hold subdued annual gala
-
Austria trials DNA testing to uncover honey fraud
-
Trump trade war pushes firms to consider stockpiling
-
D'Backs' Suarez becomes 19th MLB player to hit four homers in one game
-
Continuity or rupture: what direction for the next pope?
-
Surridge scores four as Nashville smash seven past Chicago
-
Chinese tea hub branches into coffee as tastes change
-
Diplomacy likely to trump geography in choice of new pope
-
All eyes turn to conclave after Pope Francis's funeral
-
Doves, deaths and rations: Papal elections over time
-
Progressive Canadians say social issues blown off election agenda
-
Liverpool primed for Premier League title party
-
Buenos Aires bids farewell to Francis with tears, calls to action
-
Thunder sweep past Grizzlies in NBA playoffs, Cavs on brink
-
Major blast at Iran port kills 14, injures 750
-
'What we live for': Kounde after winning Barca Copa del Rey final

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, discusses positive preclinical data recently presented at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Watch the "What This Means" video here
Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced that announced that Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic participated in a Virtual Investor "What This Means" segment.

As part of the segment, Dr. Bissonnette discussed key highlights from the Company's recent positive data demonstrating DNase I significantly improves efficacy of anti-CTLA-4 immune checkpoint blockade in preclinical models of microsatellite stable/mismatch repair proficient (MSS/MMRp) colorectal carcinoma (CRC) which was presented at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. MSS/MMRp CRC represents approximately 85% of CRC patients, and for which immune checkpoint blockade agents have provided meager benefit.
The Virtual Investor "What This Means" segment featuring Xenetic is now available here.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
For more information, please visit the Company's website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," "remain," "focus", "confidence in", "potential", and other words of similar meaning, including, but not limited to, all statements regarding expectations for our DNase-base oncology platform, including statements regarding: our growing body of preclinical data evaluating the DNase-based oncology platform across a number of high-value oncology indications, ongoing progress towards first in human clinical study for locally advanced or metastatic solid tumors, our strategic focus on exploratory investigator-initiated studies with institutional partners, including leveraging institutional partnerships to drive our development strategy, our focus on advancing innovative immune-oncology technologies addressing hard to treat cancers, our expectations regarding preclinical data generated to date, our focus on building a growing body of data and further developing our pipeline to build value in the near and long term, our plans regarding presentations of the results of preclinical data, the DNase platform improving outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, and our focus on advancing our systemic DNase program towards Phase 1 clinical development as an adjunctive therapy for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors. Any forward-looking statements contained herein are based on current expectations and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements, or results to differ materially from the activities and results anticipated in forward-looking statements. Important factors that could cause actual activities, performance, achievements, or results to differ materially from such plans, estimates or expectations include, among others, (1) unexpected costs, charges or expenses resulting from our manufacturing and collaboration agreements; (2) unexpected costs, charges or expenses resulting from the licensing of the DNase platform; (3) uncertainty of the expected financial performance of the Company following the licensing of the DNase platform; (4) failure to realize the anticipated potential of the DNase or PolyXen technologies; (5) the ability of the Company to obtain funding and implement its business strategy; and (6) other risk factors as detailed from time to time in the Company's reports filed with the SEC, including its annual report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues, such as the COVID-19 outbreak, and geopolitical events, such as the conflicts in the Ukraine and in the Middle East, on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions, litigation, and shareholder activism, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.
CONTACT:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
[email protected]
SOURCE: Xenetic Biosciences, Inc.
F.Schneider--AMWN